Trial reportAnnals of surgery2025
Multicenter Randomised Controlled Trial of Single Versus Double Venous Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation: Venous Outflow in Liver Transplantation Trial.
Trial report in Annals of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Safety and feasibility of robot-assisted remote radical gastrectomy for gastric cancer based on 5G communication technology (FUTURE-04): a prospective, single-arm clinical trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Trial
- Article
- Human acellular dermal matrix for middle hepatic vein reconstruction in living donor liver transplantation: a prospective feasibility and safety study.International journal of surgery (London, England) · 2026Article
- Optimizing venous outflow reconstruction for V5 & V8 in right-lobe living-donor liver transplantation: "half-circumferential anastomosis" using autologous vein grafts.Hepatobiliary surgery and nutrition · 2025Article
- Telesurgery across continents: a scoping review.Journal of robotic surgery · 2025Article
- Society of Robotic Surgery (SRS) special meeting in 2024: insights from the telesurgery consensus meeting.Journal of robotic surgery · 2025Article
- Global trends and insights of telesurgery research: a bibliometric analysis of publications since the 21st century.Surgical endoscopy · 2025Article
- Telesurgery: current status and strategies for latency reduction.Journal of robotic surgery · 2025Review
- International multispecialty consensus statement and expert opinion of best practices in telesurgery.Journal of robotic surgery · 2025Article
- Expanding access to high-quality surgical care in Africa: a landmark achievement in telesurgery.Journal of robotic surgery · 2025Article
- Minimally Invasive Liver Transplantation: The Recipient Operation.Journal of clinical and experimental hepatologyReview
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare early patency and outcomes of single outflow [single outflow technique (SOT)] and double outflow [double outflow technique (DOT)] reconstruction in right lobe living donor liver transplantation (RtLDLT) in a multicenter open-labeled randomized controlled trial.
backgroundOptimum graft venous outflow is a key factor in determining outcomes of RtLDLT. There are no data directly comparing SOT and DOT techniques of graft outflow reconstruction.
methodsAdult patients undergoing RtLDLT needing anterior sector vein reconstruction were enrolled. A prosthetic graft was used to create a neo-middle hepatic vein (neoMHV). Web-based permuted block randomization was used to allocate patients to SOT or DOT (1:1) before graft implantation. The primary endpoint was neoMHV patency for up to 6 weeks. Secondary endpoints were postoperative morbidity and survival. Intention-to-treat and as-treated analyses are reported.
resultsFive centers randomized 219 patients to SOT (n = 110) or DOT (n = 109). Both groups were similar in baseline characteristics. SOT had better neoMHV patency at 2 weeks (92.5% vs 82.9%, P = 0.032), 4 weeks (84% vs 69%, P = 0.011) but not at 6 weeks (69.5% vs 59.2%, P = 0.124). Cox proportional hazards analysis revealed DOT [hazard ratio: 1.56 (95% CI = 1.02, 2.4); P = 0.041] and use of Dacron graft [hazard ratio: 2.83 (95% CI = 1.16, 6.94), P = 0.023] as independent risk factors for neoMHV thrombosis. SOT was associated with better in-hospital survival (97.3% vs 90.8%; P = 0.044) but similar 1-year survival (89% vs 85%, P = 0.340). SOT was associated with improved survival in patients who developed early allograft dysfunction or needed reoperation.
conclusionsSOT has better early neoMHV patency than DOT and may be associated with better early survival.
Indexed as
Identifiers
39660425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.